摘要
目的探讨四联疗法联合双歧杆菌三联活菌治疗幽门螺杆菌(Hp)阳性胃溃疡的临床疗效。方法选取医院2022年4月至2023年4月收治的幽门螺杆蓖(Hp)阳性胃溃疡患者68例,按随机数字表法分为观察组和对照组,各34例。两组患者均予常规四联疗法(雷贝拉唑钠+胶体果胶秘+克拉霉素+阿莫西林),观察组患者加服双歧杆菌三联活菌。两组均持续治疗4周。结果观察组患者治疗总有效率为96.12%,显著高于对照组的76.47%(P<0.05)。与对照组比较,观察组患者治疗后的白细胞介素6、白细胞介素7、基质金属蛋白酶9、降钙素原、表皮生长因子水平均显著降低,临床症状评分显著降低(P<0.05);Hp根除率显著升高,胃溃疡复发率显著降低(P<0.05)。两组患者不良反应发生率无显著差异(P>0.05)。结论四联疗法联合双歧杆菌三联活菌治疗Hp阳性胃溃疡,可改善患者的临床症状及炎性因子水平。
Objective To investigate the clinical efficacy of quadruple therapy combined with triple active bifidobacteria in the treatment of Hp positive gastric ulcers.Methods Sixty eight patients with Helicobacter pylori(Hp)positive gastric ulcers admitted to the hospital from April 2022 to April 2023 were randomly divided into the observation group and the control group by the random number table method,with 34 cases in each group.Both groups were given conventional quadruple therapy(rabeprazole sodium+colloidal pectin secret+clarithromycin+amoxicillin),while the observation group was given triple live bifidobacteria.Both groups received continuous treatment for 4 weeks.Results The total effective rate of treatment in the observation group was 96.12%,which was significantly higher than 76.47%in the control group(P<0.05).Compared with those in the control group,the levels of interleukin-6,interleukin-7,matrix metalloproteinase 9,procalcitonin,and epidermal growth factor in the observation group were significantly reduced after treatment,and the clinical symptom scores in the observation group significantly reduced(P<0.05).The eradication rate of Hp in the observation group significantly increased,and the recurrence rate of gastric ulcer in the observation group significantly decreased(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion The combination of quadruple therapy and triple active bifidobacteria in the treatment of Hp positive gastric ulcers can improve the symptoms and inflammatory factor levels.
作者
王燕
李红
宋建国
蔡娜
刘靓芸
艾力菲拉·艾尔肯
WANG Yan;LI Hong;SONG Jianguo;CAI Na;LIU Liangyun;Ailifila AI'ERKEN(Xinjiang Uygur Autonomous Region Second Poverty Alleviation Hospital·Xinjiang Uygur Autonomous Region Fifth People's Hospital,Urumqi,Xinjiang,China 830026)
出处
《中国药业》
CAS
2024年第S02期54-56,共3页
China Pharmaceuticals
关键词
四联疗法
双歧杆菌三联活菌胶囊
幽门螺杆菌
胃溃疡
quadruple therapy
bifidobacterium triple viable capsules
Helicobacter pylori
gastric ulcer